BPC-157 and TB-500 Compared
BPC-157 has a published 15-residue reference sequence. The name TB-500 has been used for a preparation in which researchers identified an acetylated fragment of thymosin beta-4. In a blend labelled with both names, each identity and each amount needs its own entry on the specification. [1] [2]
Compare the identity records
| Question | BPC-157 | TB-500 |
|---|---|---|
| Reference description | 15-residue sequence in the cited study | Supplier name requiring an exact sequence and modification record |
| Key naming issue | Supplied form and quantity basis | Full-length thymosin-beta-4 versus a defined fragment cannot be assumed |
| Lot evidence needed | Identity and content for the specified BPC entity | Identity and content for the resolved TB entity |
| Nominal amount in the catalogue blend | 5 mg BPC-157. Check the form and mass basis. | 5 mg TB-500. Resolve the entity, then check its mass basis. |
Chang and colleagues report GEPPPGKPADDAGLV for their BPC-157. Esposito and colleagues identified Ac-LKKTETQ in the separate TB-500 sample they analysed. These two results give you specific sequences to compare with a supplier’s answer. They do not establish which TB-500 entity is in the catalogue blend. [1] [2]
Why research findings cannot be added together
The two papers answer different questions. One investigated cultured tendon fibroblasts exposed to BPC-157. The other identified a molecule in a TB-500 preparation. Neither tested a BPC-157/TB-500 mixture. A claim about their interaction would need a study of the specified mixture with suitable single-component comparisons. [1] [2]
For the individual research records, open the BPC-157 profile and the TB-500 and thymosin beta-4 profile. Keep the molecular names, the tested preparation and the experimental endpoint together when comparing findings.
What to check on the 5 mg + 5 mg blend record
The BPC-157 5 mg + TB-500 5 mg listing gives a nominal amount for each name. Ask how the two components are combined, what each mass represents and which lot result measures each one. One chromatographic purity figure for the mixture leaves the amount of each constituent unresolved.
When the documentation arrives, match two identity results and two quantity entries to the same finished lot. Use single compounds versus blends to interpret a stated mass ratio and batch documentation to request any missing field.
Follow the comparison
| Resource | Why open it |
|---|---|
| Co-Formulated Research Blends | Find the two blend records and their component-evidence questions. |
| Repair and Tissue Research Peptides | Browse the tissue-research category and its distinct identity questions. |
| Compound Index | Find another molecular profile without confusing it with a vial. |
| Compound Comparisons | Choose a comparison by its specific identity question. |
Sources and scope
- Chang et al. (2014). BPC-157 and growth-hormone receptor expression. Molecules.Methods section 4.2 gives the BPC-157 sequence used in this rat tendon-cell experiment.
- Esposito et al. (2012). TB-500 fragment characterisation. Drug Testing and Analysis.The investigators characterised the acetylated fragment in a particular TB-500 preparation. The blend sold here was outside the study.